Literature DB >> 23295230

Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Andrea Orsi1, Filippo Ansaldi, Daniela de Florentiis, Antonella Ceravolo, Valentina Parodi, Paola Canepa, Martina Coppelli, Giancarlo Icardi, Paolo Durando.   

Abstract

Antigenic drift, the evolutionary mechanism of influenza viruses, results in an increased susceptibility of vaccinated subjects against circulating viruses. New vaccines able to grant a broader and cross-reactive immune response against drifted influenza variants are needed. Several strategies were explored to enhance the immunogenicity of plain vaccines: adjuvants, carriers and intradermal administration of influenza vaccine emerge as a promising options. To evaluate the ability of a MF59-adjuvanted and intradermal influenza vaccine to elicit an effective antibody response against circulating viruses presenting antigenic patterns different from those of the vaccine strains, we compared antibody responses elicited by "implemented" vaccines and conventional intramuscular trivalent inactivated vaccine against heterologous circulating influenza A viruses. Different studies, simulating different epidemiological pictures produced by the natural antigenic drift of seasonal influenza viruses, highlighted the superior cross-reactivity of the antibodies elicited by MF59 and intradermal vaccines, compared with subunit or split vaccine against heterologous viruses.

Keywords:  MF59™; adjuvants; antigenic drift; cross-protection; influenza vaccine; intradermal

Mesh:

Substances:

Year:  2013        PMID: 23295230      PMCID: PMC3891715          DOI: 10.4161/hv.23239

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  89 in total

1.  Epidemiological and virological assessment of influenza activity in Europe during the 2003-2004 season.

Authors:  W J Paget; T J Meerhoff; A Meijer
Journal:  Euro Surveill       Date:  2005-04

2.  Epidermal DNA vaccine for influenza is immunogenic in humans.

Authors:  Robert J Drape; Michael D Macklin; Lori J Barr; Suzanne Jones; Joel R Haynes; Hansi J Dean
Journal:  Vaccine       Date:  2005-08-19       Impact factor: 3.641

3.  New A/H3N2 influenza variant: a small genetic evolution but a heavy burden on the Italian population during the 2004-2005 season.

Authors:  Filippo Ansaldi; Giancarlo Icardi; Roberto Gasparini; Cesare Campello; Simona Puzelli; Antonino Bella; Isabella Donatelli; Stefania Salmaso; Pietro Crovari
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

4.  Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine.

Authors:  Noriko Kojimahara; Akiko Maeda; Tetsuo Kase; Naohito Yamaguchi
Journal:  Vaccine       Date:  2006-05-26       Impact factor: 3.641

5.  Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses.

Authors:  Filippo Ansaldi; Sabrina Bacilieri; Federica Banfi; Paolo Durando; Laura Sticchi; Giancarlo Icardi; Roberto Gasparini
Journal:  Clin Vaccine Immunol       Date:  2006-01

6.  Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

Authors:  Iain Stephenson; Roberto Bugarini; Karl G Nicholson; Audino Podda; John M Wood; Maria C Zambon; Jacqueline M Katz
Journal:  J Infect Dis       Date:  2005-03-14       Impact factor: 5.226

7.  Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene.

Authors:  Giuseppe Del Giudice; Elena Fragapane; Roberto Bugarini; Maninder Hora; Thomas Henriksson; Emanuela Palla; Derek O'hagan; John Donnelly; Rino Rappuoli; Audino Podda
Journal:  Clin Vaccine Immunol       Date:  2006-09

8.  Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.

Authors:  Elisabetta Bianchi; Xiaoping Liang; Paolo Ingallinella; Marco Finotto; Michael A Chastain; Jiang Fan; Tong-Ming Fu; Hong Chang Song; Melanie S Horton; Daniel C Freed; Walter Manger; Emily Wen; Li Shi; Roxana Ionescu; Colleen Price; Marc Wenger; Emilio A Emini; Riccardo Cortese; Gennaro Ciliberto; John W Shiver; Antonello Pessi
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

9.  Evidence of a cross-protective immune response to influenza A in the cotton rat model.

Authors:  Timothy M Straight; Martin G Ottolini; Gregory A Prince; Maryna C Eichelberger
Journal:  Vaccine       Date:  2006-06-13       Impact factor: 3.641

10.  An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.

Authors:  Giuseppe Del Giudice; Anne Katrin Hilbert; Roberto Bugarini; Ada Minutello; Olga Popova; Daniela Toneatto; Ines Schoendorf; Astrid Borkowski; Rino Rappuoli; Audino Podda
Journal:  Vaccine       Date:  2006-01-19       Impact factor: 3.641

View more
  11 in total

1.  Immunogenicity and Safety of Intradermal Influenza Vaccine in the Elderly: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Claudia Pileggi; Valentina Mascaro; Aida Bianco; Carmelo G A Nobile; Maria Pavia
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

2.  A New Nano Adjuvant of PF3 Used for an Enhanced Hepatitis B Vaccine.

Authors:  Pu Shan; Zhibiao Wang; Jilai Li; Duoqian Wei; Zhuan Zhang; Shaojie Hao; Yibo Hou; Yunyang Wang; Shuxiang Li; Xudong Wang; Jing Xu
Journal:  Front Bioeng Biotechnol       Date:  2022-05-10

3.  The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway.

Authors:  Sonia Jain; Parakkal Jovvian George; Wanyan Deng; Joseph Koussa; Kaela Parkhouse; Scott E Hensley; Jiu Jiang; Jie Lu; Zhuyun Liu; Junfei Wei; Bin Zhan; Maria Elena Bottazzi; Hao Shen; Sara Lustigman
Journal:  Vaccine       Date:  2018-06-14       Impact factor: 3.641

4.  Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains.

Authors:  Barbara Camilloni; Michela Basileo; Angela Di Martino; Isabella Donatelli; Anna Maria Iorio
Journal:  Immun Ageing       Date:  2014-05-16       Impact factor: 6.400

5.  A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.

Authors:  Mark Mullikin; Litjen Tan; Jeroen P Jansen; Marc Van Ranst; Norbert Farkas; Eckhardt Petri
Journal:  Infect Dis Ther       Date:  2015-09-09

Review 6.  AS03- and MF59-Adjuvanted Influenza Vaccines in Children.

Authors:  Amanda L Wilkins; Dmitri Kazmin; Giorgio Napolitani; Elizabeth A Clutterbuck; Bali Pulendran; Claire-Anne Siegrist; Andrew J Pollard
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

Review 7.  Influenza vaccination in healthcare workers: A comprehensive critical appraisal of the literature.

Authors:  Guglielmo Dini; Alessandra Toletone; Laura Sticchi; Andrea Orsi; Nicola Luigi Bragazzi; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2017-10-20       Impact factor: 3.452

Review 8.  Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives.

Authors:  Angelika Wagner; Birgit Weinberger
Journal:  Front Immunol       Date:  2020-04-23       Impact factor: 7.561

Review 9.  Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults.

Authors:  Theodore F Tsai
Journal:  Infect Chemother       Date:  2013-06-26

10.  Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.

Authors:  Diletta Magini; Cinzia Giovani; Simona Mangiavacchi; Silvia Maccari; Raffaella Cecchi; Jeffrey B Ulmer; Ennio De Gregorio; Andrew J Geall; Michela Brazzoli; Sylvie Bertholet
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.